Literature DB >> 27835721

Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment.

Jeffrey Habert1,2, Martin A Katzman3, Oloruntoba J Oluboka4, Roger S McIntyre5, Diane McIntosh6, Glenda M MacQueen7, Atul Khullar8, Roumen V Milev9, Kevin D Kjernisted6, Pratap R Chokka8, Sidney H Kennedy10.   

Abstract

OBJECTIVE: This article presents the case that a more rapid, individualized approach to treating major depressive disorder (MDD) may increase the likelihood of achieving full symptomatic and functional recovery for individual patients and that studies show it is possible to make earlier decisions about appropriateness of treatment in order to rapidly optimize that treatment. DATA SOURCES: A PubMed search was conducted using terms including major depressive disorder, early improvement, predictor, duration of untreated illness, and function. English-language articles published before September 2015 were included. Additional studies were found within identified research articles and reviews. STUDY SELECTION: Thirty antidepressant studies reporting predictor criteria and outcome measures are included in this review. DATA EXTRACTION: Studies were reviewed to extract definitions of predictors, outcome measures, and results of the predictor analysis. Results were summarized separately for studies reporting effects of early improvement, baseline characteristics, and duration of untreated depression.
RESULTS: Shorter duration of the current depressive episode and duration of untreated depression are associated with better symptomatic and functional outcomes in MDD. Early improvement of depressive symptoms predicts positive symptomatic outcomes (response and remission), and early functional improvement predicts an increased likelihood of functional remission.
CONCLUSIONS: The approach to treatment of depression that exhibits the greatest potential for achieving full symptomatic and functional recovery is early optimized treatment: early diagnosis followed by rapid individualized treatment. Monitoring symptoms and function early in treatment is crucial to ensuring that patients do not remain on ineffective or poorly tolerated treatment, which may delay recovery and heighten the risk of residual functional deficits. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27835721     DOI: 10.4088/PCC.15r01926

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN: 2155-7780


  25 in total

Review 1.  Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Claire Brutocao; Feras Zaiem; Mouaz Alsawas; Allison S Morrow; M Hassan Murad; Asma Javed
Journal:  Endocrine       Date:  2018-07-31       Impact factor: 3.633

2.  In pursuit of full recovery in major depressive disorder.

Authors:  Vicent-Gil M; Serra-Blasco M; Navarra-Ventura G; Trujols J; Balanzá-Martínez V; Portella Mj; Cardoner N
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-09-09       Impact factor: 5.760

3.  Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life.

Authors:  Michael Cronquist Christensen; Hongye Ren; Andrea Fagiolini
Journal:  Ann Gen Psychiatry       Date:  2022-06-20       Impact factor: 3.301

4.  The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Jingjing Zhou; Jian Yang; Xuequan Zhu; Tarek Zghoul; Lei Feng; Runsen Chen; Gang Wang
Journal:  Ther Adv Psychopharmacol       Date:  2020-07-01

5.  Clinical characteristics associated with therapeutic nonadherence of the patients with major depressive disorder: A report on the National Survey on Symptomatology of Depression in China.

Authors:  Qian Zhou; Zhi-Guo Wu; Yun Wang; Xiao-Hua Liu; Jun Chen; Yong Wang; You-Song Su; Chen Zhang; Dai-Hui Peng; Wu Hong; Yi-Ru Fang
Journal:  CNS Neurosci Ther       Date:  2018-07-11       Impact factor: 5.243

6.  Functional impairment among people diagnosed with depression in primary healthcare in rural Ethiopia: a comparative cross-sectional study.

Authors:  Kassahun Habtamu; Girmay Medhin; Medhin Selamu; Kebede Tirfessa; Charlotte Hanlon; Abebaw Fekadu
Journal:  Int J Ment Health Syst       Date:  2019-07-17

7.  Cost-Effectiveness of a Web-Based Program for Residual Depressive Symptoms: Mindful Mood Balance.

Authors:  Jennifer M Boggs; Debra P Ritzwoller; Arne Beck; Sona Dimidjian; Zindel V Segal
Journal:  Psychiatr Serv       Date:  2021-07-29       Impact factor: 3.084

8.  Comorbidities, Depression Severity, and Circadian Rhythms Disturbances as Clinical Correlates of Duration of Untreated Illness in Affective Disorders.

Authors:  Giulia Menculini; Norma Verdolini; Francesca Brufani; Valentina Pierotti; Federica Cirimbilli; Agata Di Buò; Giulio Spollon; Filippo De Giorgi; Tiziana Sciarma; Alfonso Tortorella; Patrizia Moretti
Journal:  Medicina (Kaunas)       Date:  2021-05-08       Impact factor: 2.430

Review 9.  Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.

Authors:  Oloruntoba J Oluboka; Martin A Katzman; Jeffrey Habert; Diane McIntosh; Glenda M MacQueen; Roumen V Milev; Roger S McIntyre; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

Review 10.  Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review.

Authors:  Andrea Fiorillo; Bernardo Carpiniello; Serafino De Giorgi; Silvestro La Pia; Giuseppe Maina; Gaia Sampogna; Edoardo Spina; Alfonso Tortorella; Antonio Vita
Journal:  Front Psychiatry       Date:  2018-10-11       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.